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It is now evident that most if not all major intrastrain  crossreactive idiotypes 
(CRI) I  result  from  the  expression  of unmutated  germline  genes  or  germline 
genes that have undergone a  moderate degree of somatic mutation (1-1 1). The 
association with germline genes can account for the ubiquitous presence of such 
idiotypes within a strain (12), as contrasted with private idiotypes, which may be 
the products of highly mutated genes (13). 
In  general,  there  appears  to be  no restriction  of expression  of heavy chain 
isotype in CRIs.  This includes the expression of IgE, which has been identified 
in CRI-bearing antibodies with specificities for GAT (14,  15), Ars (16), and PC 
(17). 
The number of somatic mutations expressed in CRI + antibodies increases with 
time  after  immunization.  For  example,  in  the  phenyloxazolone system,  mAb 
prepared with spleens taken  1 wk after primary immunization reflect very few 
mutations, whereas mutations are frequent 1 wk later (18,  19). In the PC system, 
mutations are much more common in IgG or IgA than in IgM mAb bearing the 
major  CRI  (2).  Whether  this  reflects time-dependence  of mutations  (18,  20), 
association  of mutations  with  a  class  switch  (2),  or a  combination  of the  two 
mechanisms is uncertain. 
Although IgE antibodies bearing CRIs have been identified, there are no data 
available on their amino acid sequences.  Such data are of general interest; also, 
the degree of somatic mutation may relate to the mechanism of the IgM to IgE 
switch. This paper presents data on the primary structures of two IgE mAb that 
express idiotypes associated with antibodies to the Ars hapten in A/J mice. 
Materials and  Methods 
Mice.  A/J and (BALB/c ×  A/J)F~  (CAF~) mice were purchased  from The Jackson 
Laboratory (Bar Harbor, ME). Mice were 8-12 wk old at the start of an experiment. 
Hybridomas.  Hybridomas were prepared according to K6hler and  Milstein  (21), as 
modified by Gefter et al.  (22).  The hybridorna that produces protein  R16.7  (anti-Ars, 
This work was supported by grants AI-22068 and AI-10947 from the National Institutes of Health, 
Bethesda, MD. 
Abbreviations used in this paper: CDR, complementarity-determining region; CRI, crossreactive 
idiotype; CRIA, major intrastrain CRI of anti-Ars in A/J mice; CRIm, minor intrastrain CR[ of anti- 
Ars in A/J mice. 
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CRIA  + [major intrastrain  CRI of anti-Ars in A/J  mice], IgG1,) was described previously 
(23).  A  hybridoma  producing  mAb SE20.2  (anti-Ars,  CRIA  +,  IgL) (24)  was prepared 
using mesenteric  lymph node cells from an A/J  mouse immunized i.p.  three times at 2- 
wk  intervals,  with  5  ~g  portions  of KLH-Ars in  alum.  A  fourth  inoculation,  in  saline 
without alum, was given i.p. 2 wk later, 3 d before the fusion. The myeloma cell line used 
was  the  nonsecretor  Sp2/0-Agl4  (25).  Supernatants  were  screened  for  IgE  anti-Ars 
production  and  for the  presence  of CRIA by the  RIA described  below.  A  hybridoma 
secreting mAb SE1.3  (anti-Ars,  CRI,,,  ÷ [minor intrastrain  CRI of anti-Ars in A/J mice], 
lgE~) was prepared  using spleen cells from an  A/J mouse that had been irradiated  (600 
rad) and had received 5 x  I 0 v splenic leukocytes, pooled from two donor A/J mice. The 
donors had  been  immunized  three  times at  2-wk intervals with  5 ~g  KLH-Ars in alum 
and  were  sacrificed  4  wk  after  the  last  inoculation.  Recipients  were  immunized  i.p. 
immediately after  the adoptive transfer  with  5  ~g  KLH-Ars in alum,  and  fusions  were 
carried out 7  d  later.  The hybridomas secreting mAb SE20.2 or SE1.3 were cloned by 
limiting dilution.  Hybridomas were grown i.p. in CAFI mice. Pristane (0.5 ml) was given 
1-3 wk before injecting tumor cells.  For mRNA sequencing, the tumor cells were grown 
in culture medium (DMEM containing 10% FCS). 
Assay for  Total or  IgE Anti-Ars.  The  total  concentration  of anti-Ars  antibodies  was 
determined by using a polyvinylchloride microtiter plate, the wells of which were coated 
with BSA-Ars (26).  Final development was carried out with  J2~I-labeled,  affinity-purified 
rabbit anti-mouse Fab. For IgE anti-Ars, a similar assay was used, but l~SI-labeled,  affinity- 
purified  rabbit anti-mouse  IgE was used as the developing reagent  (27).  Since mAb or 
hybridoma culture supernatants  were assayed, competition by large amounts of non-lgE 
anti-Ars (28) was not a significant factor in the assays. 
Assays for CRIA and CRI,,.  The RIA for CRIA (12) made use of 10 ng of ~SI-labeled 
mAb R16.7  (CRIA+),  and  enough  rabbit anti-Id to bind  50-60%  of the  labeled  ligand. 
Complexes were precipitated  with excess goat anti-rabbit  IgG that had previously been 
adsorbed with  mouse  IgG. The concentration  of CRIA in  unknown,  unlabeled  samples 
was quantified through their capacity to inhibit binding of the labeled ligand.  Unlabeled 
mAb R 16.7 was used as the standard; 7-12 ng was required for 50% inhibition. 
Antibodies expressing CRI., are defined as those that share some but not all  idiotopes 
with antibodies expressing CRI^. Since some idiotopes are shared,  CRIJ  antibodies are 
bound by anti-CRIA, but CRI,,,  + antibodies cannot displace CRIA  + antibodies completely 
from anti-CRIA. The lgE mAb expressing CRI,,, (SE1.3) was identified by its binding to 
anti-ld (R16.7), and by the failure of a large amount to cause 50% inhibition in the assay 
for CRIA (see Results). R16.7 is a prototype of the CRIa family. 
Affinity Pur~cation of Antibodies.  Anti-Ars antibodies were purified by passage over a 
colunm of bovine gamma globulin (BGG)-Ars conjugated to Sepharose 4  B, followed by 
elution with 0.5 M sodium p-arsanilate, in Tris HCI buffer, pH 8.0 (23). 
Recombination  of H  and L  Chains.  The  method  of Bridges and  Little  (29)  was used 
with  some  modification.  Antibodies  were  reduced  with  0.01  M  DTT  (Calbiochem- 
Behring, San Diego, CA) for 2 h at room temperature,  then alkylated, in an ice bath, for 
15 min with 0.06 M iodoacetamide, (Sigma Chemical Co., St.  Louis, MO) that had been 
further recrystallized from distilled  water.  This  was followed by dialysis against  neutral 
buffer. To separate  H and L chains, the protein was dialyzed against  1 M propionic acid 
and 4.5 M urea, then 20-30 mg was applied to a column of Sephadex G-100, equilibrated 
with  the  same solution.  The solvent  used  for elution  was  1 M  propionic acid  (without 
urea). Good separation of H and L chains was obtained; the separation was monitored by 
electrophoresis on a  10% polyacrylamide gel in the presence of SDS under nonreducing 
conditions.  To recombine chains,  an  optical  absorbance  ratio  (280  nm) of 1.8:1  (H/L 
chain) was used.  The proteins were mixed while  in  1 M  propionic acid, dialyzed twice 
against distilled water, then against neutral Tris HCI buffer. 
Sequencing  of V  Regions  of mRNA for  H  and  L  Chains.  mRNA  was  isolated  from 
hybridomas essentially as described by Palmiter (30), who used other tissues.  Briefly,  1-3 
x  108 cells were suspended in neutral Tris buffer containing 2% Triton X-100, and lysed 
in a  Dounce homogenizer. Cell  debris  was removed by centrifugation.  Polysomes were 
precipitated  by adjusting  the  MgCI.,  concentration  to  100  raM,  and  were  isolated  by HABA  ET  AL.  293 
TABLE  I 
Oligonucleotide Primers Used  for mRNA Sequencing 
Amino acid po- 
sition of first 5' 
nucleotide in 
oligomer 
Sequence of primer  Source 
131 in C.1 
99 in V. 
89 in V~ 
122 in C. 
86 in V. 
66 in V, 








OCS Laboratories, Denton, TX (32) 
Prepared by K. Meek* 
C. Milstein and C. Berek 
OCS Laboratories (33) 
Prepared by K. Meek* 
C. Milstein and C. Berek 
Prepared by K. Meek* 
* Prepared using an Biosearch, Inc. (San Rafael, CA) oligonucleotide synthesizer. 
centrifugation through  100 mM sucrose at 12,000 g. Polysomes were resuspended in 20 
mM  Hepes  buffer,  multiply extracted  with  a  phenol/chloroform  mixture,  and  finally 
extracted with chloroform. Nucleic acids were precipitated from the aqueous phase with 
2.5  volumes of ethanol.  Poly-A  + mRNA was then  isolated on  oligo-dT-cellulose (New 
England BioLabs, Beverly, MA). 
mRNA  for  VL or  VH  regions  was  sequenced  by  the  chain-termination  method,  as 
described by Hamlyn et al. (31).  In brief, a synthetic oligodeoxynucleotide primer is used, 
which  hybridizes to an  mRNA sequence a  short distance beyond  the  3'  end of the  V 
region. One or more primers hybridizing within the V region are needed to extend the 
sequence further toward the N-terminus.  Primer extension with reverse transcriptase is 
carried out in the presence of the four unlabeled dideoxynucleotides, which act as chain 
terminators. ~2p-labeled  ATP or GTP is also present in the mixture. After a 30-min chase 
with an excess of the four deoxynucleotides, the mRNA is hydrolyzed with NaOH, diluted 
1:1  with  formamide,  and  subjected  to  electrophoresis  on  an  8%  polyacrylamide gel, 
followed by autoradiography. Information on the primers used is given in Table I. 
Protein Sequencing of SE20.2 H and L Chains.  Protein sequencing was carried out for 
the N-terminal regions of the H and L chains (positions 1-25) as described (34). 
Results 
Fig.  1  shows  nucleotide  and  amino  acid  sequences  of the  V,  regions  of IgE 
anti-Ars  mAb  SE20.2  and  SE1.3.  For  SE1.3,  only  nucleotide  sequencing  was 
carried  out.  For SE20.2,  the  complete nucleotide  sequences  were obtained  for 
V.DHJ. and VLJL. In addition,  the N-terminal sequences of both chains of SE20.2 
were obtained by protein sequencing (positions  1-25 of both V. and VL). There 
was complete agreement  between  the  peptide  and  nucleic  acid  sequences.  For 
SE20.2  (but not SE1.3),  the mRNA  sequence for large segments of both chains 
was determined  independently in two laboratories. This resulted in the elimina- 
tion of a  few uncertainties  that would otherwise have been present.  In addition, 
there was disagreement with respect to one nucleotide,  corresponding to amino 
acid 96 of the light chain. 
We  will  discuss  the  V.  segments  (positions  1-98)  first.  They are  compared 
with  the  corresponding sequence  of mAb 36-65,  which  has been  shown  (6)  to 
have a V. segment encoded by an unmutated germline gene. This gene (generally 
in  a  mutated  form) is believed to encode the  V. segment of all CRIA  + anti-Ars 
mAb studied so far. When the nucleotide sequence of SE20.2 is compared to the 
germline  sequence,  there  are  only  three  nucleotide  substitutions  in  the  V~ 
segment (positions  1-98),  two of which  occur  in  complementarity-determining 294  PRIMARY STRUCTURE  OF  IDIOTYPE-BEARING lgE 
10  20 
E  V  Q  L  Q  Q  S  G  A  E  L  V  R  A  G  S  S  V  K  M  S  C  K  A  S 
36-65  GAGGTTCAGCTTCAGCAGTCTGGAGCTGAGCTGGTGAGGGCTGGGTCCTCAGTG~u~GATGTCCTGCAAGGCTTCT 
SE20.2 
SEI.3  (  Not  Sequenced  ) 
30  40  50 
G  Y  T  F  T  S  Y  G  I  N  W  V  K  Q  R  P  G  Q  G  L  E  W  I  G  Y 
36-65  GGATATACATTCACAAGC  TACGGTATAAAC  TGGGTGAAACAGAGGCC  TGGACAGGGCC  TGGAATGGATTGGATAT 
SE20.2 
SE1.3 
60  70 
I  N  P  G  N  G  Y  T  K  Y  N  E  K  F  K  G  K  T  T  L  T  V  D  K  S 
36-65  ATTAATC  CTGGAAATGGTTATACTAAGTACAATGAGAAGTTCAAGGGCAAGACCACAC  TGACTGTAGACAAATC  C 
SE20.2 --  T----C 
80  90  98 
S  S  T  A  Y  M  Q  L  R  S  L  T  S  E  D  c  S  A  V  Y  F  C  A  R 
36-65,  TCCAGCACAGCCTACATGCAGCTCAGAAGCCTGACATCTGAGGATTCTGCAGTCTATTTCTGTGCAAGA 
SE20.2  C- 
I  D segment  I  110  3  segment  120-- I 
S  V  Y  Y  G  G  S  Y  Y  F  O  Y  W  G  Q  G  T  T  L  T  V  S  S 
36-65  TCGGTCI'ACTATGGTGGTAGT  TACTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA  (JH  2) 
SE20.2 ~GT- 
SEI.3  --(:CAT  TTC  X  XXT---C  (  Not  Sequenced  )  (JH  2) 
FIGURE  1.  Nucleotide and deduced amino acid sequences of the VH regions of two IgE anti- 
Ars mAb, SE20.2 and SE1.3. They are compared with the corresponding sequences of mAb 
36-65,  whose V. segment (1-98)  is virtually identical in nucleotide sequence to that of a 
putative germline gene (6). A solid line indicates identity with the 36-65 nucleotide sequence. 
An uncertainty in the nucleotide or amino acid sequence is indicated by an X or by a question 
mark, respectively. Amino  acid differences are boxed. 
region  2  (CDR2)  and  cause  amino  acid  substitutions.  The  third  is  a  silent 
substitution at amino acid position 72. 
There  are  more  substitutions  in  the  V,  segment  (positions  1-98)  of mAb 
SE1.3  (CRIm+), which  differs from the  germline-encoded amino acid sequence 
at five positions, three of which are in CDR2. There is uncertainty for one amino 
acid,  at  position  43.  Again,  all  differences  from  the  germline-encoded amino 
acid sequence involve a  single nucleotide substitution.  The first  17 amino acids 
of the V. segment of SE1.3 were not determined. 
As indicated in  Fig.  1,  the  D. segments of 36-65 and  SE20.2 have the same 
length (eight amino acids),  which is characteristic of the CRIA  + mAb sequenced 
so far,  with very few exceptions (35 and E.  Rosen and P.  Robbins, unpublished 
results).  There  is  one  amino  acid  substitution  (position  100)  in  SE20.2,  as 
compared to  36-65;  this  involves all  three  nucleotides  of the  codon.  The  D. 
segment of SE1.3 is one amino acid longer than that of 36-65 or SE20.2 (shown 
as  an  insertion  of phenylalanine between  positions  105  and  106).  In  addition, HABA  ET  AL.  295 
I  5  I0  15  20  25 
R16.7  D  I  Q  M  T  Q  T  T  S  S  L  S  A  S  L  G  D  R  V  T  I  S  C  R  A 
SE1.3  (  Not  Sequenced  )TCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCA 
SE20.2  GATATCCAGATGACACAGACTACA  A  C  c 
30  35  40  45  50 
R16.7  S  Q  D  I  S  N  Y  L  N  W Y  Q  Q  K  P  D  G  T  V  K  L  L  [  Y  Y 
SEI.3  AGTCAGGACATTAGCAATTATTTAAACTGGTATCABCAGAAACCAGATGGAACTGTTAAACTCCTGATCTACTAC 
SE20.2 
55  60  65  70  75 
R16.7  T  S  R  L  H  S  G  V  P  S  R  F  S  G  S  G  S  B  T  D  Y  S  L  T  I 
SE1.3  ACATCAAGATTACACT~AgGAGTC  CCATC AAGGT~XAGTgGCAGTGGGTCTGgAACAGAT  TATTCTCTCAC CATT 
SE20.2  C  --TTC- 
~0  85  ~0  g5 [--J  Segc~ent-- 
R16.7  S  N  L  E  E  D  I  A  Y  F  C  Q  6  N  S  L  P  R  T  F  B  G 
SE1.3  AGCAACCTGGAGCAAGAAGATATT  GCC ACT  TACTTTTGCCAACAGGGT AATA~GC TTCCTX~GACGTTCGGTGGA 
m  N 
SE20.2  --6  c 
---J  Segment  108 
R16.7  G  T  K  k  E  I  K  R 
SEI.3  GGCACC  X~GCTGG/~TC X/~J~CGG 
SE20.2  A  G  ~  •  'A 
FIGURE 2.  Comparison of the VL amino acid sequences of mAb SEI.3 and SE20.2 (both IgE, 
anti-Ars), with that of R16.7 (]gG1,), a strongly CRIA  + anti-Ars mAb (23). An uncertainty in 
the nucleotide or amino acid sequence is indicated by an X or by a question mark, respectively. 
Amino acid differences are boxed. 
there  is a  substitution  (His  for  Val)  at  position  100,  again  involving all  three 
nucleotides. 
The partial sequences obtained for theJH regions of SE20.2 and SE1.3 indicate 
that  they are J.l  and JH2,  respectively. With rare exceptions (36), CRIA  + mAb 
use J,2.  Thus,  SE20.2,  which  is  CRIA  ÷,  constitutes  another  exception  to  this 
general rule. The partial JH sequence of SE20.2 agrees with the germline BALB/c 
J.1  sequence (37 and data not shown), except for two nucleotide substitutions, 
one of which is at the D-J junction. 
Fig. 2 shows nucleotide sequences and corresponding amino acid sequences of 
the entire  VK region  of the  IgE anti-Ars  mAb, SE20.2 (CRIA  +) and all but the 
first eight amino acids of SE 1.3 (CRIm+). The deduced amino acid sequences are 
compared with that of the V, region of mAb R16.7 (38), a prototypical CRIA  + 
anti-Ars  mAb.  In  addition,  nucleotide  sequences  of  SE1.3  and  SE20.2  are 
compared with one another.  Nucleotide sequences are not available for the V~ 
of R16.7.  For  SE20.2  there  are  three  differences  as  compared  with  the  V~ 
segment of R 16.7 (positions 1-95), two of which are in CDRs. In addition, there 
is one uncertainty in the nucleotide sequence of SE20.2. 
A comparison of the amino acid sequence of the V, segment of SE 1.3 (positions 
1-95)  with  that  of  R16.7  shows  only  one  definite  amino  acid  substitution, 296  PRIMARY  STRUCTURE  OF  IDIOTYPE-BEARING  IgE 
TABLE  II 
In Vitro Recombination  of H and L Chains from Anti-Ars mAb 
Apparent concentration (#g/ml) 
Exp.  Protein  From  From anti-  From anti-  CRIA assay § 
OD2s0  Ars titer*  Ars titer* 
Intact 
1  R16.7  300  302 ~  0  8 
2  SE1.3  300  230  301  >3,000  (9) 
3  SE20.2  300  285  300 ~  10 
4  NonspecificlgG  300  0  0  >3,000  (13) 
Reduced, alkylated 
5  R16.7  300  278  0  6 
6  SE1.3  300  66  92  >3,000 
Recombinant 
7  H~67LI~.v  300  283  0  7 
8  HI6.TLl.3  300  271  1  8 
9  H~6vLN  300  2  0  340 
10  HI .sLmv  300  35  53  250 
11  H~ ~L~.~  300  28  52  >3,100 
12  H~3LN  300  2  5  >3,300 
13  HNL~6v  300  2  0  385 
14  HNL~  300  3  1  >3,000 






* Using t25I-labeled,  affinity-purified rabbit anti-mouse Fab as the developing reagent. R16.7  was 
used as the standard. 
* Using P251-1abeled, affinity-purified rabbit anti-mouse IgE as the developing reagent. SE20.2 was 
used as the standard. 
Amount (ng) required for 50% inhibition in the RIA for CRIA.  Numbers in parentheses refer to 
percent inhibition by weight (in ng) specified. 
II Note that these are the standards used. 
(position 93  in CDR3),  and two uncertainties. 8  of the 95  positions in  the V, 
segment of SE1.3 were not sequenced. 
The V~ nucleotide sequences of SE20.2 and SE1.3 are strikingly similar; there 
are  only three  differences (and  four  uncertainties), strongly supporting  their 
derivation from the same V, germline gene. 
The JK regions of SE1.3 and SE20.2 are both JK1. In comparison with the J,l 
amino acid sequence of R16.7, there are no substitutions (but three uncertainties) 
in SE1.3 and one substitution, as well as one uncertainty, in SE20.2. 
Idiotypic Properties of mAb SE20. 2 and SE1.3.  Table II shows data on inhibition 
by SE20.2 and SE1.3 in the RIA for CRIA. SE20.2 expresses CRIA; its inhibitory 
capacity is comparable to that of R16.7, a prototype of CRIA + mAb. In contrast, 
SE1.3  is a  very poor inhibitor, causing only 9%  inhibition when 3,000  ng was 
tested. SE1.3 is, however, bound by anti-CRIA. It was completely removed upon 
passage through a column of Sepharose 4 B, to which an IgG fraction ofanti-Id, 
specific  for  mAb  R16.7,  was  conjugated.  This  experiment  was  done  with  a 
culture supernatant of the SE1.3 hybridoma; all anti-Ars activity was bound by 
the  column.  Another  experiment  made  use  of  125I-labeled,  affinity-purified 
SE 1.3.  10 ng was added to varying dilutions of rabbit anti-Id(R 16.7) antiserum, 
and complexes were precipitated with goat anti-rabbit IgG; rabbit antiovalbumin HABA  ET  AL.  297 
antiserum was present as carrier.  92% of the radioactivity was bound by a  1:80 
dilution of the anti-Id antiserum. 
The fact that  SE1.3 is bound by anti-CRIA but fails to inhibit strongly in the 
RIA for CRIA indicates that it possesses one or more, but not all idiotopes that 
constitute the CRIA idiotype. We have referred to such molecules as expressing 
a minor idiotype, or CRIm (39). 2 
Recombination  of H and L Chains.  The amino acid sequence data indicate that 
mAb SE20.2 and SEI.3 both have VH (1-98) and VL (1-95) regions that are very 
similar to those associated with CRIA. As indicated above, SE1.3 is a  very poor 
inhibitor in the RIA for CRIA. In an effort to ascertain whether this is attributable 
to its H chain, L chain, or both, we carried out chain recombination experiments. 
The results are shown in Table II. The following points emerge from the data. 
The  most  significant  conclusion  is  that  the  L  chain  of  SE1.3  (CRIm +)  is 
equivalent  to  that  of R16.7  (CRIA  +)  with  respect  to  mediating  expression  of 
CRIA. The recombinant molecule, HI6.TL~.3 (the prefixes R and SE are omitted), 
is  nearly  equivalent  to  R16.7,  or  to  the  recombinant,  HI6.7LI6.7 in  inhibitory 
capacity in the assay for CRIA (Exps.  1, 7, and 8).  Conversely, the recombinant 
of the L chain of R16.7 with the H  chain of SE1.3 expresses CRIA very poorly 
(250  ng  required  for  50%  inhibition  as compared  to  7  ng for the autologous 
recombinant,  HI6.7LI6.7;  Exps.  7 and  10).  These results indicate that the failure 
of SE1.3 to express CRIA is attributable to its H chain rather than to its L chain. 
The weak inhibition  by H1.3L1~.7 in the assay for CRIA (Exp.  10) may be due to 
slight residual contamination of L16.7  by H~67. This is supported by the fact that 
the recombinant  HNLI6.7 (where  N  denotes nonspecific IgG) has a  similar,  very 
weak inhibitory capacity (385 ng required for 50% inhibition; Exp.  13). 
Thus,  the  data  strongly  suggest  that  the  L  chain  of SE1.3  is  idiotypically 
equivalent to that of R 16.7. The conclusion that H~3 is not idiotypicaly equivalent 
to H16.7 is weakened by evidence that the procedures used modified the properties 
of the ~ chain of S E 1.3. First, -70% of the Ars-binding activity of SE 1.3 was lost 
simply as a consequence of reduction and alkylation (Exps. 2 and 6). In addition, 
the autologous recombinant  HL3L~ 3 expressed only ~12%  of the Ars-binding 
activity of the intact molecule (Exps. 2 and  11).  It thus appears that e chains may 
be more easily denatured than 3~ chains under the conditions used. Nevertheless, 
the  virtual  identity  of L~3 and  L16.7  in  their  serological properties  and  amino 
acid sequences, and the fact that SE1.3 is idiotypically deficient with respect to 
CRIA, indicate that the defect resides in the V. and/or DH segments. 
Discussion 
The results presented here provide the first data on the primary structure of 
V regions of IgE antibodies that express a major idiotype (CRIA). This permits a 
comparison  with  the  corresponding  germline-encoded  sequence  of the  CRIA- 
associated VH segment.  The corresponding germline V, sequence is not known, 
but comparisons among known amino acid sequences are informative (see below). 
The principal question we wanted to address was the extent of somatic mutation 
that would be found in V regions of IgE antibodies. This, in turn,  might reflect 
the stage of development of the B cell when the switch to IgE synthesis occurred. 
2 The primary structure of SE1.3, described in this paper, indicates that it may be a member of 
the 91A3 V~ family described by Milner and Capra. (40). 298  PRIMARY  STRUCTURE  OF  IDIOTYPE-BEARING  lgE 
There is now strong evidence (2,  3,  9,  18) that antibodies produced very early 
in a primary response exhibit very few or no mutations, and that mutations tend 
to accumulate with time after immunization. Although mutations were found to 
be more prevalent in IgG than in IgM antibodies expressing the T 15 idiotype, a 
direct association of mutations with a class switch is unproven. For example, very 
early antiphenyloxazolone antibodies of the IgG class exhibit very few mutations 
(18). 
Our results indicate that an IgE CRIA + antibody may express a very limited 
number of somatic  mutations. The  V~  sequence  of the  CRIA + IgE antibody, 
SE20.2, is particularly informative. In the V. segment (positions 1-98) there are 
only  three  nucleotide differences (and  one  uncertainty) as  compared  to  the 
germline nucleotide sequence. This results in two amino acid substitutions, both 
in CDR2.  It is remarkable that mAb 93G7  (CRIA  +) has precisely the same two 
nucleotide substitutions in  CDR2  (41).  Since SE20.2  is a  relatively late  mAb, 
prepared  from a  spleen taken after four inoculations of antigen over an  8-wk 
period, it is evident that the switch to IgE biosynthesis can be accomplished with 
very  few  associated  somatic  mutations.  This  is  supported  by  the  amino  acid 
sequence of the VK segment (1-95), which shows only three definite substitutions 
(at positions 30,  76,  and  93)  with respect to  R16.7,  a  prototype of the CRIA 
family. It  should  be  noted,  however,  that  the  V~  amino acid  sequences  of a 
number of CRIA + mAb show very few differences (38, 42). 
For SE1.3, which also has a  VH sequence very similar to that encoded by the 
putative  germiine  gene,  there  are  five  nucleotide  substitutions  among  243 
nucleotides for which a comparison with the germline sequence of  the VR segment 
is possible.  In  the  V~  region (1-95),  there  is  one amino acid difference from 
R16.7, at position 93 (and two uncertainties) among the 87 positions for which 
a comparison can be made. D and J sequences are discussed below. It is evident, 
then, that our  IgE antibodies exhibit somatic mutations, but that they are no 
more frequent, particularly for SE20.2, than is typically seen in CRIA + IgG anti- 
Ars  mAb prepared  after repeated  inoculation of antigen  (34,  38,  43).  These 
results  are  of interest  with  respect  to  mechanisms  of immunoglobulin class 
switching. Mongini et al. (44) have presented evidence suggesting that the IgM 
to IgE switch may proceed by a direct pathway, without an intermediate switch 
to an IgG subclass.  This is consistent with the small number of somatic mutations 
that we observed in IgE, either on the basis that somatic mutation is associated 
with a class switch (2),  or that mutations occur simply as a  function of time or 
number of cell divisions (9). 
Some other features of the amino acid sequences are of interest.  One is the 
presence ofaJ.l sequence in SE20.2, a strongly CRIa  + anti-Ars antibody. Nearly 
all other anti-Ars CRIA + antibodies sequenced have proven to be J,2, although 
at least one exception (with J.4) has been reported previously (36). 
Another question of interest is the basis for the deficiency of CRIA-associated 
idiotopes in SE1.3. An obvious possibility is the presence of an extra amino acid 
in the D region of SEI.3  (Fig.  1).  The presence of eight amino acids in the D 
region is an almost constant feature of CRIA  + anti-Ars antibodies, although a 
weakly CR]A + mAb (I 23E6) with a nine-amino acid D region has been described 
previously (45).  It is also possible that amino acid substitutions in the V, segment 
are in part responsible; there are five known substitutions in SE1.3 with respect HABA ET  AL.  299 
to the germline-encoded sequence, of which three are in CDR2. The presence 
of arginine at position 54 has not previously been observed. The deficiency of 
idiotopes in SE1.3 is evidently not attributable to VL orJL, since the recombinant 
molecule HI6.7 LI.3 fully expressed CRIA and anti-Ars activity. 
On  this  basis,  one  would predict  that  the  H  chains of SE1.3  would fail to 
reconstitute CRIA when combined with L16.7. This was in fact observed, but the 
results are not germane because of evidence for partial denaturation of e chains 
upon reduction and alkylation (see Results). 
A  novel observation is the presence of a  cysteine (or half-cystine) residue in 
the J.1  region (of SE20.2).  It will be of interest to ascertain whether this amino 
acid is present in a disulfide-bonded form. 
Summary 
We have obtained amino acid sequences (by mRNA and amino acid sequenc- 
ing) for two IgEK mAb that have specificity for the Ars hapten group and are 
related to the major idiotypic family, CRIA (crossreactive idiotype A),  in the A 
strain  of mouse.  One  mAb,  SE20.2,  fully expresses  CRIA;  the  other,  SE1.3, 
possesses  some  but  not  all  of the  characteristic  idiotopes.  Both  IgE  proteins 
contain V,  and  VK  segments that are  closely related to  those associated with 
CR|A. The D segment of SE20.2 is also typical of CRIA  + mAb, but that of SE1.3 
is one amino acid residue longer.  Chain recombination experiments indicated 
that the  L  chain  of SE1.3  is  fully capable  of supporting CRIA  expression.  Its 
deficiency with respect to idiotopes of CRIA was attributed to the extra amino 
acid in the D region and/or substitutions in the V. segment. 
A major objective was to ascertain the frequency of somatic mutations in IgE. 
For the V. segment (amino acids 1-98) of SE20.2, there are only three nucleotide 
differences and one uncertainty with respect to the nucleotide sequence of the 
germline gene associated with CRIA. A somewhat higher frequency of substitu- 
tions is present in the V. segment of SE1.3. The V~ amino acid sequences of the 
IgE proteins are nearly identical to those of a prototype of the CRIA family, mAb 
R 16.7. The results are discussed with reference to the mechanism of the IgM to 
IgE switch. 
We thank Dr. J. D. Capra for helpful discussions. 
Received for publication  17 March 1986. 
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